Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

Kevin M. McKown, Laura D. Carbone, Stanley B. Kaplan, Jacob A. Aelion, Kristine M. Lohr, Michael A. Cremer, Juan Bustillo, Miguel Gonzalez, Gurjit Kaeley, Elaine L. Steere, Grant W. Somes, Linda K. Myers, Jerome M. Seyer, Andrew H. Kang, Arnold E. Postlethwaite

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.

Original languageEnglish (US)
Pages (from-to)1204-1208
Number of pages5
JournalArthritis and Rheumatism
Issue number6
StatePublished - Jun 1999
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)


Dive into the research topics of 'Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this